Literature DB >> 16455331

Minimally invasive sentinel lymph node mapping of the pig colon with Lymphoseek.

Anne M Wallace1, Scott J Ellner, Jeanette Méndez, Carl K Hoh, Carol E Salem, Carl M Bosch, Richard C Orahood, David R Vera.   

Abstract

BACKGROUND: Minimally invasive surgery and sentinel node mapping are being utilized increasingly in colon cancer surgery. Making these techniques efficient and easy to perform will be essential for the future of this and other gastrointestinal operations. The purpose of this study was to test a new laparoscopic gamma detection probe for minimally invasive sentinel node mapping of the colon, while utilizing Lymphoseek, a radiopharmaceutical specifically designed for sentinel lymph node (SLN) detection.
METHODS: Eight anesthetized pigs received an endoscopic co-injection of Lymphoseek and Isosulfan Blue in the colon. The laparoscopic gamma detector, inserted via a 12-mm trocar, was used to identify radioactive sentinel lymph nodes. The reliability of the side-viewing probe was tested using a radioactive source. All blue and radioactive lymph nodes were excised and the signal-to-background ratio (S/B) and percent of injected dose (%ID) were measured.
RESULTS: The probe was easy to maneuver and led to efficient visualization of the radioactive node. The side port allowed for better distinction between injection site scatter and sentinel node activity. The reliability of the probe was validated by an identification rate of 97%. At least one SLN was detected for each pig; two SLNs were detected in two pigs. All SLNs were stained blue. The SLN S/B ranged from 38 to 315 and the %ID ranged from 0.06% to 2.01%. Sentinel nodes were found within 10 minutes.
CONCLUSIONS: Minimally invasive sentinel node mapping with the radiopharmaceutical Lymphoseek and a side-viewing gamma detector yielded high S/B and directionality for accurate mapping of gastrointestinal sentinel lymph nodes within minutes of radiotracer administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455331     DOI: 10.1016/j.surg.2005.06.038

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek.

Authors:  Anne M Wallace; Carl K Hoh; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2007-08-09       Impact factor: 2.408

2.  Preclinical evaluation of robotic-assisted sentinel lymph node fluorescence imaging.

Authors:  Michael A Liss; Salman Farshchi-Heydari; Zhengtao Qin; Sean A Hickey; David J Hall; Christopher J Kane; David R Vera
Journal:  J Nucl Med       Date:  2014-07-14       Impact factor: 10.057

Review 3.  Management of nodal disease from colon cancer in the laparoscopic era.

Authors:  Corrado Pedrazzani; Lelde Lauka; Simone Sforza; Andrea Ruzzenente; Filippo Nifosì; GianGaetano Delaini; Alfredo Guglielmi
Journal:  Int J Colorectal Dis       Date:  2014-11-22       Impact factor: 2.571

Review 4.  The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Authors:  Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath
Journal:  Nucl Med Biol       Date:  2015-12-03       Impact factor: 2.408

5.  A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer.

Authors:  Stanley P L Leong; Julian Kim; Merrick Ross; Mark Faries; Charles R Scoggins; Wendy L Rich Metz; Frederick O Cope; Richard C Orahood
Journal:  Ann Surg Oncol       Date:  2011-02-18       Impact factor: 5.344

6.  γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).

Authors:  Abul K Azad; Murugesan V S Rajaram; Wendy L Metz; Frederick O Cope; Michael S Blue; David R Vera; Larry S Schlesinger
Journal:  J Immunol       Date:  2015-07-22       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.